openPR Logo
Press release


09-11-2012 02:59 PM CET | Science & Education

Press release from: Proteros biostructures GmbH

Largest-ever Financing allows for Expansion of Drug Discovery Capabilities

MARTINSRIED, GERMANY (August 6th, 2012) – Proteros biostructures GmbH (‘Proteros’) announced today that it had successfully closed a financing round of five million Euros to fund the continued expansion and growth of the company.

The financing round was led by BayBG, a key equity investor for Proteros. The financing round is the third and largest investment into the firm since the inception of Proteros. Two new financial institutions were part of a consortium alongside of BayBG. The proceeds will be used to support the development of the company, with a particular focus on investment into Proteros’ further downstream drug discovery capabilities. Moreover, the financing will strengthen the Company’s equity capital base and reduce its current overall financing and debt servicing costs.

In tandem with the financing, Proteros announced it will re-align the Company’s organization and expand the integrated drug discovery services business. Prominent in these measures will be the deployment of further medicinal chemistry staff that will assist in growing the Company’s drug discovery capabilities, which are being expanded in response to market demand. Proteros’ world-class core analytical services capabilities, including X-Ray crystallography, kinetic/thermodynamic profiling and custom protein supply, will continue to form the basis for future development.

Dr. Torsten Neuefeind, Chief Executive Officer and founder of Proteros, stated:”We are happy to have closed our third, and to-date, largest-ever financing round. Additionally we are also very pleased to welcome two new financing partners in this financing round, as well as to receive the strong continued support of BayBG. With the Company’s strong partnerships associated with its analytics business, Proteros is ideally positioned to make the next step into drug discovery applications.”

About Proteros:
Proteros is a privately held Life Sciences company based in Munich, Germany that provides services and proprietary technologies to support drug discovery programs of the largest pharmaceutical companies. The company accelerates and improves protein structure analysis and structure-based drug discovery with its expertise and unique technologies for crystallography and fragment-based lead generation. Proteros complements its clients’ capabilities. Proteros currently provides services for more than eighty pharmaceutical and biotechnology clients in North America, Europe and Asia.

Proteros biostructures GmbH
Dr. Torsten Neuefeind
Bunsenstr. 7a
D-82152 Planegg-Martinsried
Phone: +49 (0) 89 700 761-0

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release PROTEROS ANNOUNCES SUCCESSFUL CLOSE OF FINANCING ROUND here

News-ID: 231784 • Views: 1842

More Releases from Proteros biostructures GmbH

Proteros and Eisai Co., Ltd enter into Integrated Lead Discovery Collaboration
Martinsried (Germany), April 16, 2012. Proteros biostructures GmbH today announced that the company has entered into a research collaboration with Eisai Co., Ltd (Japan) to identify small molecule inhibitors against a target selected by Eisai in the field of immunology. Under the agreement Proteros will deliver a novel lead compound applying its integrated lead discovery platform that includes X-Ray structural biology, biophysical screening and profiling, novel fragment libraries and medicinal chemistry
Proteros announces the appointment of Dr. Klaus Hinterding as Chief Scientific O …
Martinsried, Germany, February 9, 2012. Proteros biostructures GmbH (Proteros) announced today that Dr. Klaus Hinterding, formerly at Hoffmann-La Roche Ltd. (Roche), has joined the company as Chief Scientific Officer and member of the management board. Dr. Hinterding brings to Proteros considerable pharmaceutical industry experience that spans early research through to clinical development in various therapeutic areas. At Novartis, his research contributed to the understanding of the mode-of-action of GilenyaTM, licensed for
Janssen Pharmaceutica NV and Proteros expand relationship and enter into Global …
Martinsried Jan 09, 2012. Janssen Research & Development, a division of Janssen Pharmaceutica NV (“Janssen”) and Proteros biostructures GmbH (“Proteros”) today announced they have entered into a long-term global service agreement granting Janssen privileged access to Proteros portfolio of discovery technologies and services. Under the agreement Janssen will have broad access to Proteros’ drug discovery technologies, including structural biology, biophysical screening and profiling service, novel fragment libraries, medicinal chemistry expertise and
Proteros has relocated to a tailor-made facility in Martinsried
Martinsried, October 24th 2011. Proteros biostructures GmbH is further extending its business capacities by moving into a new building in Munich-Martinsried, one of the leading Biotech locations in Germany. After a two-year planning period, Proteros has reached an important milestone in its development by centralizing all operations within a purpose-built facility. The 4,000 square-meter of laboratory and office space, worth a total of about 15 M €, has been optimally designed

All 5 Releases

More Releases for Company’s

Refresh, Rebrand, Relook - Inkcups Now Rebrands to Match Company’s Essence
Danvers, MA. – July 26, 2017 – Inkcups is the world’s leading provider for innovative printing equipment, supplies, and solutions to customers in the promotional, apparel, and industrial markets worldwide. Founded in 2001 by CEO Ben Adner, Inkcups has proven itself in the industry; not only as a company who provides groundbreaking products, but also as a company who works with their customers by guiding, teaching, and ensuring a solution
SovTech launches every company’s on-demand development department.
The SovTech Dev Shop, an on-demand custom software development provider, today announced the launch of their on-demand software developer network. The Dev Shop offers a simple solution for enterprises and startups to submit their development requirements and have a dedicated team of experts designing & coding within a matter of days. SovTech Dev Shop offers on-demand bespoke software development solutions to enterprises and startups of any size. With SovTech, customers
SCETI K.K. Company’s General and Deputy Manager visit Elabscience
SCETI K.K. Company’s General and Deputy Manager visit Elabscience The SCETI K.K. Company’s general manager Tetsuya Toida Ph.D. and deputy manager Atsushi Takaguchi visited Elabscience. According to report, SCETI K.K. has been cooperated with Elabscience since 2014. Elabscience's manager Wang held a meeting with them. He introduced Elabsicence's development: "with an increasing number of professional researchers joined Elabscience, more sophisticated equipment using and perfect experimental process training, the quality of our
National Gift Card names Eric Thiegs company’s new President
National Gift Card Corp. (NGC), one of the leading B2B suppliers of incentive and loyalty gift cards, has appointed Eric Thiegs as the company’s new president, effective immediately. Thiegs, 43, formerly Senior Vice President of Sales and Marketing at NGC, reports to Chief Executive Officer Adam Van Witzenburg, who previously held both positions and retains the CEO role. Thiegs joined National Gift Card in 2013 and will now be responsible for continuing
Furniture Marketing Group Relocates To Billingsley Company’s International Bus …
Billingsley Company today announced the relocation of Furniture Marketing Group (FMG) from 6200 Tennyson Parkway to Billingsley’s International Business Park. FMG is expected to move into its new offices at 6100 W. Plano Parkway later this year. Furniture Marketing Group, a total office solutions provider, will occupy approximately 17,000 sq. ft. according to Trevor Franke, principal, Peloton Commercial Real Estate. Franke, who brokered the 10-year lease agreement, says the new office
Metrics Names Renee Smith as Company’s First Validation Manager
GREENVILLE, N.C. – Having experienced a significant increase in clients and projects, Metrics Inc. has created a new validation manager position and appointed Reneé L. Smith to serve in it. Smith brings nearly 10 years of validation management experience to her new role, and is especially knowledgeable about master site plan protocols for equipment, facilities, utilities and operations. Most recently, she served as senior validation associate for a large commercial